Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding. Four...

Source: Critical Care - June 16, 2022 Category: Intensive Care Authors: Olivia S. Costa, Stuart J. Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J. Christoph, Belinda Lovelace and Craig I. Coleman Tags: Research Source Type: research